Selecting deep brain stimulation or infusion therapies in advanced Parkinson's disease: An evidence-based review

Jens Volkmann, Alberto Albanese, Angelo Antonini, K. Ray Chaudhuri, Carl E. Clarke, Rob M A De Bie, Günther Deuschl, Karla Eggert, Jean Luc Houeto, Jaime Kulisevsky, Dag Nyholm, Per Odin, Karen Østergaard, Werner Poewe, Pierre Pollak, Jose Martin Rabey, Olivier Rascol, Evzen Ruzicka, Michael Samuel, Hans SpeelmanOlof Sydow, Francesc Valldeoriola, Chris Van Der Linden, Wolfgang Oertel

Research output: Contribution to journalArticle

Abstract

Motor complications in Parkinson's disease (PD) result from the short half-life and irregular plasma fluctuations of oral levodopa. When strategies of providing more continuous dopaminergic stimulation by adjusting oral medication fail, patients may be candidates for one of three device-aided therapies: deep brain stimulation (DBS), continuous subcutaneous apomorphine infusion, or continuous duodenal/jejunal levodopa/carbidopa pump infusion (DLI). These therapies differ in their invasiveness, side-effect profile, and the need for nursing care. So far, very few comparative studies have evaluated the efficacy of the three device-aided therapies for specific motor problems in advanced PD. As a result, neurologists currently lack guidance as to which therapy could be most appropriate for a particular PD patient. A group of experts knowledgeable in all three therapies reviewed the currently available literature for each treatment and identified variables of clinical relevance for choosing one of the three options such as type of motor problems, age, and cognitive and psychiatric status. For each scenario, pragmatic and (if available) evidence-based recommendations are provided as to which patients could be candidates for either DBS, DLI, or subcutaneous apomorphine.

Original languageEnglish
Pages (from-to)2701-2714
Number of pages14
JournalJournal of Neurology
Volume260
Issue number11
DOIs
Publication statusPublished - Nov 2013

Fingerprint

Deep Brain Stimulation
Parkinson Disease
Subcutaneous Infusions
Infusion Pumps
Apomorphine
Therapeutics
Equipment and Supplies
Levodopa
Nursing Care
Psychiatry
Half-Life

Keywords

  • Apomorphine
  • Deep brain stimulation
  • Duodenal levodopa infusion
  • Parkinson's disease

ASJC Scopus subject areas

  • Clinical Neurology
  • Neurology

Cite this

Volkmann, J., Albanese, A., Antonini, A., Chaudhuri, K. R., Clarke, C. E., De Bie, R. M. A., ... Oertel, W. (2013). Selecting deep brain stimulation or infusion therapies in advanced Parkinson's disease: An evidence-based review. Journal of Neurology, 260(11), 2701-2714. https://doi.org/10.1007/s00415-012-6798-6

Selecting deep brain stimulation or infusion therapies in advanced Parkinson's disease : An evidence-based review. / Volkmann, Jens; Albanese, Alberto; Antonini, Angelo; Chaudhuri, K. Ray; Clarke, Carl E.; De Bie, Rob M A; Deuschl, Günther; Eggert, Karla; Houeto, Jean Luc; Kulisevsky, Jaime; Nyholm, Dag; Odin, Per; Østergaard, Karen; Poewe, Werner; Pollak, Pierre; Rabey, Jose Martin; Rascol, Olivier; Ruzicka, Evzen; Samuel, Michael; Speelman, Hans; Sydow, Olof; Valldeoriola, Francesc; Van Der Linden, Chris; Oertel, Wolfgang.

In: Journal of Neurology, Vol. 260, No. 11, 11.2013, p. 2701-2714.

Research output: Contribution to journalArticle

Volkmann, J, Albanese, A, Antonini, A, Chaudhuri, KR, Clarke, CE, De Bie, RMA, Deuschl, G, Eggert, K, Houeto, JL, Kulisevsky, J, Nyholm, D, Odin, P, Østergaard, K, Poewe, W, Pollak, P, Rabey, JM, Rascol, O, Ruzicka, E, Samuel, M, Speelman, H, Sydow, O, Valldeoriola, F, Van Der Linden, C & Oertel, W 2013, 'Selecting deep brain stimulation or infusion therapies in advanced Parkinson's disease: An evidence-based review', Journal of Neurology, vol. 260, no. 11, pp. 2701-2714. https://doi.org/10.1007/s00415-012-6798-6
Volkmann, Jens ; Albanese, Alberto ; Antonini, Angelo ; Chaudhuri, K. Ray ; Clarke, Carl E. ; De Bie, Rob M A ; Deuschl, Günther ; Eggert, Karla ; Houeto, Jean Luc ; Kulisevsky, Jaime ; Nyholm, Dag ; Odin, Per ; Østergaard, Karen ; Poewe, Werner ; Pollak, Pierre ; Rabey, Jose Martin ; Rascol, Olivier ; Ruzicka, Evzen ; Samuel, Michael ; Speelman, Hans ; Sydow, Olof ; Valldeoriola, Francesc ; Van Der Linden, Chris ; Oertel, Wolfgang. / Selecting deep brain stimulation or infusion therapies in advanced Parkinson's disease : An evidence-based review. In: Journal of Neurology. 2013 ; Vol. 260, No. 11. pp. 2701-2714.
@article{97db48585ac04f39bf2d6994804f93e1,
title = "Selecting deep brain stimulation or infusion therapies in advanced Parkinson's disease: An evidence-based review",
abstract = "Motor complications in Parkinson's disease (PD) result from the short half-life and irregular plasma fluctuations of oral levodopa. When strategies of providing more continuous dopaminergic stimulation by adjusting oral medication fail, patients may be candidates for one of three device-aided therapies: deep brain stimulation (DBS), continuous subcutaneous apomorphine infusion, or continuous duodenal/jejunal levodopa/carbidopa pump infusion (DLI). These therapies differ in their invasiveness, side-effect profile, and the need for nursing care. So far, very few comparative studies have evaluated the efficacy of the three device-aided therapies for specific motor problems in advanced PD. As a result, neurologists currently lack guidance as to which therapy could be most appropriate for a particular PD patient. A group of experts knowledgeable in all three therapies reviewed the currently available literature for each treatment and identified variables of clinical relevance for choosing one of the three options such as type of motor problems, age, and cognitive and psychiatric status. For each scenario, pragmatic and (if available) evidence-based recommendations are provided as to which patients could be candidates for either DBS, DLI, or subcutaneous apomorphine.",
keywords = "Apomorphine, Deep brain stimulation, Duodenal levodopa infusion, Parkinson's disease",
author = "Jens Volkmann and Alberto Albanese and Angelo Antonini and Chaudhuri, {K. Ray} and Clarke, {Carl E.} and {De Bie}, {Rob M A} and G{\"u}nther Deuschl and Karla Eggert and Houeto, {Jean Luc} and Jaime Kulisevsky and Dag Nyholm and Per Odin and Karen {\O}stergaard and Werner Poewe and Pierre Pollak and Rabey, {Jose Martin} and Olivier Rascol and Evzen Ruzicka and Michael Samuel and Hans Speelman and Olof Sydow and Francesc Valldeoriola and {Van Der Linden}, Chris and Wolfgang Oertel",
year = "2013",
month = "11",
doi = "10.1007/s00415-012-6798-6",
language = "English",
volume = "260",
pages = "2701--2714",
journal = "Journal of Neurology",
issn = "0340-5354",
publisher = "Dr. Dietrich Steinkopff Verlag GmbH and Co. KG",
number = "11",

}

TY - JOUR

T1 - Selecting deep brain stimulation or infusion therapies in advanced Parkinson's disease

T2 - An evidence-based review

AU - Volkmann, Jens

AU - Albanese, Alberto

AU - Antonini, Angelo

AU - Chaudhuri, K. Ray

AU - Clarke, Carl E.

AU - De Bie, Rob M A

AU - Deuschl, Günther

AU - Eggert, Karla

AU - Houeto, Jean Luc

AU - Kulisevsky, Jaime

AU - Nyholm, Dag

AU - Odin, Per

AU - Østergaard, Karen

AU - Poewe, Werner

AU - Pollak, Pierre

AU - Rabey, Jose Martin

AU - Rascol, Olivier

AU - Ruzicka, Evzen

AU - Samuel, Michael

AU - Speelman, Hans

AU - Sydow, Olof

AU - Valldeoriola, Francesc

AU - Van Der Linden, Chris

AU - Oertel, Wolfgang

PY - 2013/11

Y1 - 2013/11

N2 - Motor complications in Parkinson's disease (PD) result from the short half-life and irregular plasma fluctuations of oral levodopa. When strategies of providing more continuous dopaminergic stimulation by adjusting oral medication fail, patients may be candidates for one of three device-aided therapies: deep brain stimulation (DBS), continuous subcutaneous apomorphine infusion, or continuous duodenal/jejunal levodopa/carbidopa pump infusion (DLI). These therapies differ in their invasiveness, side-effect profile, and the need for nursing care. So far, very few comparative studies have evaluated the efficacy of the three device-aided therapies for specific motor problems in advanced PD. As a result, neurologists currently lack guidance as to which therapy could be most appropriate for a particular PD patient. A group of experts knowledgeable in all three therapies reviewed the currently available literature for each treatment and identified variables of clinical relevance for choosing one of the three options such as type of motor problems, age, and cognitive and psychiatric status. For each scenario, pragmatic and (if available) evidence-based recommendations are provided as to which patients could be candidates for either DBS, DLI, or subcutaneous apomorphine.

AB - Motor complications in Parkinson's disease (PD) result from the short half-life and irregular plasma fluctuations of oral levodopa. When strategies of providing more continuous dopaminergic stimulation by adjusting oral medication fail, patients may be candidates for one of three device-aided therapies: deep brain stimulation (DBS), continuous subcutaneous apomorphine infusion, or continuous duodenal/jejunal levodopa/carbidopa pump infusion (DLI). These therapies differ in their invasiveness, side-effect profile, and the need for nursing care. So far, very few comparative studies have evaluated the efficacy of the three device-aided therapies for specific motor problems in advanced PD. As a result, neurologists currently lack guidance as to which therapy could be most appropriate for a particular PD patient. A group of experts knowledgeable in all three therapies reviewed the currently available literature for each treatment and identified variables of clinical relevance for choosing one of the three options such as type of motor problems, age, and cognitive and psychiatric status. For each scenario, pragmatic and (if available) evidence-based recommendations are provided as to which patients could be candidates for either DBS, DLI, or subcutaneous apomorphine.

KW - Apomorphine

KW - Deep brain stimulation

KW - Duodenal levodopa infusion

KW - Parkinson's disease

UR - http://www.scopus.com/inward/record.url?scp=84885108687&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84885108687&partnerID=8YFLogxK

U2 - 10.1007/s00415-012-6798-6

DO - 10.1007/s00415-012-6798-6

M3 - Article

C2 - 23287972

AN - SCOPUS:84885108687

VL - 260

SP - 2701

EP - 2714

JO - Journal of Neurology

JF - Journal of Neurology

SN - 0340-5354

IS - 11

ER -